Drugs / GV-108
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT07520214 | Sep 2025 → Dec 2027 expected | IDH-wildtype glioblastoma | Beijing Neurosurgical Institute | Enrolling by invitation | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GV-108 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07520214 ↗ |
| Modality | Messenger RNA (mRNA) | “mRNA vaccines GV-108 and GV-907” NCT07520214 ↗ |